Abviva Inc Watch

from 8-K 4 pages Placement Agent and Advisory Services Agreement

from 8-K 1 page Very Truly Yours, /S/ Jonathan F. Atzen Jonathan F. Atzen

from 10-Q 1 page Material contract

from 10KSB 1 page Promissory Note

from 8-K ~5 pages Non-Employee Interim Chief Executive Officer Engagement Agreement

from 8-K ~5 pages Mr. Ira Bodenstein, Esq. Receiver for the Estate of Efoora, Inc. Shaw Gussis Fishman Glantz Wolfson and Towbin LLC 321 N. Clark Street Suite 800 Chicago, Il 60610 Re: Offer Leiter of Intent to Acquire the Stock of Prion Developmental Laboratories, Inc

from 8-K 1 page Promissory Note

from 8-K 1 page Promissory Note

from 10QSB 5 pages Genesis Bioventures, Inc. Engagement Agreement

from 8-K 12 pages Debenture Agreement

from 10KSB 3 pages October 14, 2005 the Following Modifications in Section 5.3 (“Milestones”) Are Requested: 1. Milestone (2): Characterization of Target Protein(s) Based on Verifiable Protein Sequence(s). We Request the Milestone Date Be Moved From February 15, 2005 to December 31, 2005. 2. Milestone (3): The Filing of an FDA Application for the Current Format or Adoption of an Improved Alternate Diagnostic Format (Such as Elisa). We Request the Milestone Date Be Moved From May 15, 2005 to December 31, 2005. 3. Milestone (4): Cumulative Net Sales of at Least $350,000. We Request the Milestone Date Be Moved From November 15, 2005 to December 31, 2006. 4. Milestone (5): Cumulative Net Sales of at Least $1,300,000. We Request the Milestone Date Be Moved From November 15, 2006 to December 31, 2007. 5. Milestone (6): Increased Employee Staffing Levels From Those on May 15, 2004, Including a Senior Regulatory Person, 5 Scientists (Including Medical Technicians) and a Viable Customer Service Function (The Last of Which May Be Contracted Out). We Request the Milestone Be Eliminated. 6. Milestone (7): FDA Approval of Improved Alternate Diagnostic Format (Such as Elisa) or FDA Approval of Current Diagnostic Format. We Request the Milestone and Dates Be Reworded as Follows: FDA Approval of Current Diagnostic Format by December 31, 2008 or FDA Approval of Improved Alternate Diagnostic Format (Such as Elisa) by December 31, 2010. Milestone (1): First Commercial Sale by October 15, 2003 Was Completed on Schedule as Previously Reported to You. Ms. Robin Rasor the University of Michigan

from 10KSB 2 pages May 12, 2004 1. Milestone (2): Characterization of Target Protein(s) Based on Verifiable Protein Sequence(s). We Request the Milestone Date Be Moved From May 15, 2004 to February 15, 2005. 2. Milestone (3): The Filing of an FDA Application for the Current Format or Adoption of an Improved Alternate Diagnostic Format (Such as Elisa). We Request the Milestone Date Be Moved From November 15, 2004 to May 15, 2005. 3. Milestone (4): Cumulative Net Sales of at Least $25,000. We Request the Milestone Date Be Moved From May 15, 2005 to November 15, 2005. 4. Milestone (5): Cumulative Net Sales of at Least $100,000. We Request the Milestone Date Be Moved From May 15, 2006 to November 15, 2006. 5. Milestone (6): Increased Employee Staffing Levels From Those on May 15, 2004, Including a Senior Regulatory Person, 5 Scientists (Including Medical Technicians) and a Viable Customer Service Function (The Last of Which May Be Contracted Out). We Request the Milestone Date Be Moved From May 15, 2005 to November 15, 2005. 6. Milestone (7): FDA Approval of Improved Alternate Diagnostic Format (Such as Elisa) or FDA Approval of Current Diagnostic Format. Mr. Brice Nelson the University of Michigan Office of Technology Transfer May 12, 2004 Page 2 of 2 Thank You for Your Consideration on This Amendment. if You Agree to These Modifications, Please Indicate Your Approval Below. Meanwhile, Please Contact Me if You Have Any Questions

from 10KSB 27 pages Exclusive Distribution and License Agreement

from 10KSB 9 pages Distributor License Agreement

from 8-K 21 pages Non-Employee Interim Chief Executive Officer Engagement Agreement

from 10KSB/A ~5 pages Non-Disclosure Agreement

from 10KSB/A 1 page Service Agreement

from S-8 1 page Gbi (2004(c)) Made March 4, 2004

from S-8 1 page Stock Services Plan

from S-8 1 page Stock Services Plan